Group 1 - The company announced a leadership change, with Ms. Fu Xiao resigning as the Group President effective January 12, 2026 [1] - Ms. Fu will continue to serve as a company advisor and remain an executive director [1] - Mr. Jiang Wei has been appointed as the new President, effective January 12, 2026 [1]

Group 1 - The company announced a leadership change, with Ms. Fu Xiao resigning from her position as Group President effective January 12, 2026 [1] - Ms. Fu will continue to serve as a company advisor and remain an executive director [1] - Mr. Jiang Wei has been appointed as the new President, effective January 12, 2026 [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致之任何損失承擔任何責任。 CONCORD HEALTHCARE GROUP CO., LTD. 總裁變更 美中嘉和醫學技術發展集團股份有限公司（「本公司」，連同其附屬公司，統稱「本 集團」）董事（「董事」）會（「董事會」）宣佈，根據本集團內職務調整，付驍女士退 任本集團總裁職務，自二零二六年一月十二日起生效。付驍女士（「付女士」）將成 為本公司顧問，並繼續擔任本集團執行董事職務。 付女士已確認，彼與董事會並無任何分歧，且退任屬於正常繼任計劃，亦無其他 有關其退任之事宜須提請本公司股東（「股東」）和香港聯合交易所有限公司（「聯交 所」）垂注。 公司謹此機會對付女士在擔任總裁期間為本公司作出的寶貴貢獻致以衷心感謝。 委任總裁 董事會欣然宣佈，姜偉先生（「姜先生」）已獲委任為總裁，自二零二六年一月十二 日起生效。 美中嘉和醫學技術發展集團股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2453） 1 姜先生於二零 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年12月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 美中嘉和醫學技術發展集團股份有限公司 呈交日期: 2026年1月6日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02453 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 313,874,624 | RMB | | 1 RMB | | 313,874,624 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 313,874,624 | RMB | | 1 RMB | | 313,874,624 | | 2. 股份分類 | 普通股 | 股份類別 | ...

Core Insights - The announcement from Meizhong Jiahe marks a significant milestone for its proton therapy center in Guangzhou, indicating a successful transition from technology introduction to capability realization in the medical sector [2][5] - The healthcare industry in China is undergoing a structural adjustment, shifting from a "scale dividend" model to one focused on "capability premium," emphasizing the importance of specialized assets with high technical barriers [2] Group 1: Company Performance - Meizhong Jiahe has demonstrated its strength as an industry "standard setter," participating in the formulation of six national clinical guidelines and establishing a strong academic foundation in proton therapy [3] - The company has achieved a comprehensive breakthrough in clinical breadth, depth, and operational efficiency, completing a closed loop from "heavy asset investment" to "high-quality output" [3][4] - The proton therapy center has shown significant growth in patient intake, indicating a strong brand influence and operational efficiency, with all four treatment rooms operating at full capacity [4] Group 2: Industry Context - The recent "2025 China Social Medical New Ecology Conference" highlighted the need for sustainable clinical output from high-cost medical equipment, which is a critical measure of the level of social medical services [2] - The center's service range extends across 31 provinces and over 20 countries, showcasing its international reach in high-end medical services, particularly in pediatric proton therapy [4] - The completion of China's first proton treatment for ocular malignant melanoma in July 2025 fills a domestic gap and reinforces the center's position in high-difficulty tumor treatments [4]

Core Viewpoint - The company announced that its subsidiary, Guangzhou Taihe Oncology Hospital Proton Therapy Center, has officially operated for one year since December 16, 2024, emphasizing its commitment to enhancing clinical capabilities and international collaboration in proton therapy [1] Group 1: Operational Performance - The Guangzhou Proton Therapy Center has fully utilized its four treatment rooms, providing proton therapy services to a total of 550 patients, with over 80 new patients added each month [1] - The center's patient demographic spans across 31 provincial administrative regions in China and over 20 countries and regions, with patients ranging in age from 1 to 91 years old [1] - The center completed China's first proton therapy for choroidal malignant melanoma in July 2025, marking a significant milestone in its operational achievements [1] Group 2: Strategic Development - The company is focused on strengthening its core competitiveness in high-end medical services through continuous optimization of service processes and improvement of treatment efficiency [1] - The steady advancement of the proton therapy business has further enhanced the company's layout in the field of precision cancer treatment [1] - Future plans include ongoing enhancements in clinical capabilities and collaboration with advanced international medical institutions to keep pace with global developments in proton therapy technology [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致之任何損失承擔任何責任。 CONCORD HEALTHCARE GROUP CO., LTD. 本公告乃由美中嘉和醫學技術發展集團股份有限公司（「本公司」）董事會（「董事 會」）自願刊發。 董事會欣然宣佈，本公司子公司廣州泰和腫瘤醫院質子治療中心（以下簡稱「廣州 醫院質子中心」）自2024年12月16日起至今，已正式運營一周年。公司高度重視 質子治療中心的臨床能力建設，堅持加強與國際先進醫療機構合作科研，與國際 質子治療技術同步發展，通過引進高端醫療人才、加強技術研發與學術交流等方 式，持續提升診療水平。截至目前，廣州醫院質子中心的臨床服務能力已得到充 分驗證，各項運營指標表現良好。 廣州醫院質子中心四間質子治療室已經全部啟用，累計為550位患者提供質子治 療服務，單月新增患者超過80人，服務能力持續提升。服務患者範圍覆蓋國內31 個省級行政區以及20多個國家和地區，接受質子治療的患者年齡從1歲至91歲。 2025年7月，廣州醫 ...

Core Viewpoint - The release of the "Clinical Practice Guidelines for Ion Radiation Therapy (2025 Edition)" and the "Quality Assurance Guidelines for Proton Radiation Therapy Systems (2025 Edition)" marks the establishment of systematic and comprehensive industry standards for high-end radiation therapy in China [1][2]. Group 1: Industry Standards and Contributions - The guidelines were developed by a team including experts from Guangzhou Taihe Hospital, part of Meizhong Jiahe Medical Technology Development Group, along with top public institutions [1]. - Meizhong Jiahe has been involved in the formulation of national guidelines four times in recent years, contributing to six national standard outcomes, indicating a shift from occasional participation to a sustained and systematic role in standard-setting [1][2]. - Industry experts view participation in national standard formulation as a certification of technical and quality systems, reflecting long-term accumulation of capabilities [1]. Group 2: Competitive Position and Growth Potential - With stricter regulations and detailed standards, the industry is entering a phase where stronger capabilities lead to faster expansion, benefiting Meizhong Jiahe in approvals, collaborations, academic branding, and clinical appeal [2]. - All four proton therapy rooms at Guangzhou Taihe Hospital are now operational, leading to rapid growth in treatment volume and solidifying its position as a particle center in South China [2]. - Meizhong Jiahe's long-term performance, marked by its four entries into national guidelines and six contributions, positions it among the few social medical entities in the top tier of the industry, enhancing its competitive advantage in high-end radiation therapy [2].

Core Viewpoint - The inclusion of Guangzhou Taihe Cancer Hospital in the "Hong Kong-Macao Drug and Device Pass" list represents a significant breakthrough for the company in accessing international medical resources and enhancing its service capabilities in cancer treatment [1][2]. Group 1: Company Developments - The hospital has successfully passed the approval process to be listed as a designated medical institution under the "Hong Kong-Macao Drug and Device Pass" policy, which facilitates the introduction of innovative drugs and devices approved in Hong Kong and Macao but not yet available in mainland China [1]. - This policy is expected to broaden the legal supply channels for urgently needed clinical treatments, providing policy support for residents in the Greater Bay Area to access advanced medical services in line with international standards [1][2]. - The company has established professional barriers in precision treatment, proton therapy, and multidisciplinary diagnosis and treatment, which will be further strengthened by this new designation [1][3]. Group 2: Industry Implications - The advancement of the "Hong Kong-Macao Drug and Device Pass" not only enhances the service capabilities of individual institutions but also contributes to the construction of a high-level medical service network characterized by tiered diagnosis and regional collaboration [2]. - Designated medical institutions can attract patients from surrounding areas by introducing international innovative drugs and devices, gradually forming regional cancer treatment centers and optimizing the allocation of medical resources [2]. - The ongoing release of policy dividends in the Greater Bay Area is expected to accelerate the flow of cross-border medical resources, allowing the company to benefit continuously from its specialized and international strategic layout [2].

Core Viewpoint - Meizhong Jiahe Medical Technology Development Group has been approved to enter the "Hong Kong-Macao Drug and Medical Device Access" designated medical institution list, positioning itself as a key beneficiary of the policy and providing clear growth opportunities for investors [1][3]. Group 1: Company Developments - The approval allows Guangzhou Taihe Tumor Hospital to import and use urgently needed drugs and advanced medical devices that are already listed in Hong Kong and Macao but not yet approved in mainland China [1]. - The hospital can now introduce innovative drugs and medical devices in the oncology field, enhancing its competitive advantage and broadening its business scope [1][2]. Group 2: Industry Implications - The "Hong Kong-Macao Drug and Medical Device Access" initiative aims to improve the quality of medical services and align domestic treatments with international standards, particularly in oncology [2][3]. - The initiative is expected to reduce the treatment time gap between mainland China and international markets, particularly for diseases like breast cancer and lung cancer, thereby enhancing patient treatment options [2]. - The increased accessibility of cross-border medical resources will likely attract more patients to hospitals with such capabilities, creating a "regional treatment center" effect and increasing overall service intensity [2][3].